New biomarkers in acute kidney injury

急性肾损伤 少尿 医学 重症监护医学 肾脏疾病 无尿 肌酐 人口 内科学 肾功能 环境卫生
作者
Adam Rossiter,Ashley La,Jay L. Koyner,Lui G. Forni
出处
期刊:Critical Reviews in Clinical Laboratory Sciences [Taylor & Francis]
卷期号:61 (1): 23-44 被引量:18
标识
DOI:10.1080/10408363.2023.2242481
摘要

AbstractAcute kidney injury (AKI) is a commonly encountered clinical syndrome. Although it often complicates community acquired illness, it is more common in hospitalized patients, particularly those who are critically ill or who have undergone major surgery. Approximately 20% of hospitalized adult patients develop an AKI during their hospital care, and this rises to nearly 60% in the critically ill, depending on the population being considered. In general, AKI is more common in older adults, in those with preexisting chronic kidney disease and in those with known risk factors for AKI (including diabetes and hypertension). The development of AKI is associated with an increase in both mortality and morbidity, including the development of post-AKI chronic kidney disease. Currently, AKI is defined by a rise in serum creatinine from either a known or derived baseline value and/or oliguria or anuria. However, clinicians may fail to recognize the initial development of AKI because of a delay in the rise of serum creatinine or because of inaccurate urine output monitoring. This, in turn, delays any putative measures to treat AKI or to limit its degree. Consequently, efforts have focused on new biomarkers associated with AKI that may allow early recognition of this syndrome with the intent that this will translate into improved patient outcomes. Here we outline current biomarkers associated with AKI and explore their potential in aiding diagnosis, understanding the pathophysiology and directing therapy.Keywords: Acute kidney injuryacute kidney diseasechronic kidney diseasebiomarkers Disclosure statementJ.L.K has received consulting fees from Astute-Biomerieux, Sphingotec, Pfizer, Baxter, Mallinckrodt, Novartis, Guard Therapeutics, research funding from Astute-Biomerieux Medical, Bioporto, NxStage, Fresenius, Satellite Healthcare, and speaker fees from NxStage medical; L.G.F has received research support and lecture fees from Ortho Clinical Diagnostics, Baxter, Exthera and Biomerieux and consulting fees from La Jolla Pharmaceuticals and Paion. A.R. and A.L. declare no competing interests.Funding statementThe authors reported that there is no funding associated with the work featured in this article.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
猫南北完成签到,获得积分10
1秒前
江恋完成签到,获得积分10
4秒前
GGBOND发布了新的文献求助10
7秒前
9秒前
hhhblabla应助yyyyyyy111采纳,获得10
11秒前
哈哈发布了新的文献求助10
12秒前
17秒前
19秒前
背后初南完成签到,获得积分10
20秒前
神勇馒头完成签到,获得积分10
20秒前
GGBOND发布了新的文献求助10
21秒前
21秒前
22秒前
以戈完成签到,获得积分10
24秒前
26秒前
泡泡脑瓜发布了新的文献求助10
27秒前
358489228完成签到,获得积分10
27秒前
28秒前
xww发布了新的文献求助10
30秒前
31秒前
神勇馒头发布了新的文献求助10
34秒前
34秒前
chen完成签到,获得积分10
36秒前
cindywu发布了新的文献求助10
36秒前
贰叁发布了新的文献求助10
37秒前
38秒前
量子星尘发布了新的文献求助10
39秒前
40秒前
Lu发布了新的文献求助10
42秒前
43秒前
泡泡脑瓜关注了科研通微信公众号
44秒前
丫丫丫完成签到,获得积分20
45秒前
无花果应助GGBOND采纳,获得10
45秒前
跳跃盼波完成签到,获得积分10
47秒前
喜悦松完成签到,获得积分10
48秒前
666完成签到,获得积分10
48秒前
Jessica完成签到,获得积分10
51秒前
51秒前
汉堡包应助666采纳,获得10
52秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989115
求助须知:如何正确求助?哪些是违规求助? 3531367
关于积分的说明 11253688
捐赠科研通 3269986
什么是DOI,文献DOI怎么找? 1804868
邀请新用户注册赠送积分活动 882078
科研通“疑难数据库(出版商)”最低求助积分说明 809105